Peptide MK2 Activators for Endothelial Barrier Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions like pulmonary edema and endothelial barrier dysfunction, such as those caused by high altitude or hypoxia, are inadequate, and existing kinase inhibitors face toxicity issues and inefficacies in clinical translation.
Innovation Solution
Development of peptides comprising a transduction domain linked to a domain blocking the autoinhibitory domain of MK2, which activates MK2 to enhance endothelial barrier function and reduce permeability, thereby treating conditions like pulmonary edema and endothelial barrier disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing kinase inhibitors are used to treat endothelial barrier dysfunction, then permeability reduction is achieved, but toxicity issues arise and clinical translation efficiency is poor
Solution Approach 1:
The patent changes the molecular parameter from small-molecule kinase inhibitors to peptide-based MK2 activators. This parameter change fundamentally alters the mechanism of action while maintaining the therapeutic goal of reducing vascular permeability, thereby achieving efficacy without the toxicities associated with conventional kinase inhibitors
Solution Approach 2:
Instead of inhibiting kinases to reduce permeability, the patent inverts the approach by activating MK2 (a kinase) to achieve the same therapeutic effect. This inversion through activation rather than inhibition provides an alternative pathway that avoids the toxicity issues of kinase inhibitors while maintaining treatment efficacy
2Reliability
If peptide compounds are designed to activate MK2, then barrier integrity is enhanced and vascular leak is reduced, but peptide delivery and stability challenges arise
Solution Approach 1:
The patent uses peptide compounds as intermediary molecules that can be administered systemically to reach and activate MK2 in target tissues. These peptides serve as mediators between systemic administration and the intracellular MK2 activation pathway, overcoming delivery challenges through their ability to penetrate cellular barriers and activate the target kinase
Solution Approach 2:
The peptide compounds are designed to self-activate MK2 upon reaching the target site without requiring complex delivery systems or activation mechanisms. The peptides inherently possess the ability to cross cell membranes and directly interact with MK2, providing self-service delivery that simplifies manufacturing and administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively activate MK2, reducing vascular leak and enhancing barrier integrity, as demonstrated by their ability to counteract anthrax toxin effects and hypoxia-induced permeability increases, without significant toxicity, offering a promising treatment for various endothelial and epithelial barrier-related diseases.
Implementation Method 1
MK2 activation leads to phosphorylation of HSP27, which enhances endothelial barrier function and reduces permeability
Data Source
AI summary
Compositions and methods for activating MK2, augmenting permeability barriers, such as epithelial and/or endothelial barriers, and treating diseases, conditions, disorders, and/or injuries associated therewith, such as pulmonary edema and other lung diseases and injuries are provided herein.